Abstract: The present invention provides a method for determining a survival rate and prognosis state for a patient having esophageal carcinoma, comprising: (a) providing a tissue sample from the patient; (b) measuring a expression level of a target gene in the tissue sample from the patient using reagents specific for the target gene product that are selected from the group consisting of probes, primers, antibodies, and antibody fragments, wherein the expression level is RNA expression, a protein expression at a cellular level or a tissue level; (c) comparing the expression level to a predetermined threshold indicative of a survival rate and prognosis state for the patient; and (d) providing a survival rate and prognosis state for the patient so that care for the patient is able to be determined in accordance with the survival rate and prognosis state, wherein the target gene is peptidase inhibitor 3 (PI3).

Abstract: The present invention provides a method for predicting the survival rate and prognosis of esophageal carcinoma patients, which is characterized in examining the expression level of a specific gene, peptidase inhibitor 3 (PI3) or CD14 antigen (CD14) in a sample, and comparing to the average expression level of said specific gene from patients to determine the survival and prognosis status for esophageal cancer. The present invention further provides a kit for predicting the survival rate and prognosis of esophageal carcinoma patients.